Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
Executive Summary
Company says 75% of Medicare Part D patients who aren't eligible for low income subsidies abandon the PCSK9 inhibitor at the pharmacy counter due to $370 co-pay, which may now range from $25-$150 per dose.
You may also be interested in...
After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
After Two Jury Verdicts, Court Finds Repatha Patents Invalid
Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.
Amgen's Murdo Gordon On Generating Sales Growth In A Challenging Commercial Year
Newer products are gaining ground, but not fast enough to replace sales as blockbuster products face competition. Scrip spoke with the company's global commercial head about the strategy going forward.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
